- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 9 - Benefit Design and Making Treatment Affordable
Dr Dunn introduces the discussion of benefit design, suggesting that managed care providers may be unprepared to administer specialty drugs. He explains that specialty medications’ tiered system often does not incentivize providers to use less expensive medications. He suggests that stakeholders should reassess misaligned incentives in benefit design, especially for treatment options such as biosimilars.
Dr Quinn says that sometimes providers, including those like himself, are often unaware of the alternative options to newer, costlier drugs. Generics may be one way to offer providers and patients more cost-effective options for treating prostate cancer.
“It’s going to change, I think, our treatment,” Dr Quinn says. He adds that active management tools can help providers and patients understand the value of therapy options that provide equal benefits to costlier drugs, but for less out-of-pocket costs.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
